Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is expected to be issuing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $17.7440 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. Sight Sciences had a negative return on equity of 59.38% and a negative net margin of 64.23%.The business had revenue of $12.54 million during the quarter. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $5.10 on Tuesday. The company’s fifty day simple moving average is $3.94 and its 200-day simple moving average is $3.76. Sight Sciences has a 52 week low of $2.03 and a 52 week high of $5.32. The company has a current ratio of 10.01, a quick ratio of 9.49 and a debt-to-equity ratio of 0.57. The company has a market cap of $267.09 million, a PE ratio of -5.31 and a beta of 2.46.

Insiders Place Their Bets

In related news, CEO Paul Badawi sold 24,441 shares of the firm’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $3.34, for a total transaction of $81,632.94. Following the completion of the sale, the chief executive officer directly owned 5,962,502 shares of the company’s stock, valued at approximately $19,914,756.68. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeremy B. Hayden sold 9,731 shares of the firm’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $3.27, for a total transaction of $31,820.37. Following the sale, the insider directly owned 256,590 shares of the company’s stock, valued at approximately $839,049.30. The trade was a 3.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 40,796 shares of company stock valued at $135,173. Company insiders own 28.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of Sight Sciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 845,776 shares of the company’s stock worth $3,494,000 after buying an additional 43,791 shares during the last quarter. Strs Ohio bought a new position in shares of Sight Sciences in the 1st quarter worth about $158,000. Rhumbline Advisers lifted its position in shares of Sight Sciences by 9.6% in the 2nd quarter. Rhumbline Advisers now owns 54,597 shares of the company’s stock worth $225,000 after buying an additional 4,800 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Sight Sciences in the 1st quarter worth about $128,000. Finally, Jane Street Group LLC bought a new position in shares of Sight Sciences in the 2nd quarter worth about $148,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SGHT. Citigroup cut their target price on shares of Sight Sciences from $4.50 to $4.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 7th. Morgan Stanley raised their target price on shares of Sight Sciences from $3.00 to $4.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Lake Street Capital raised their target price on shares of Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Wall Street Zen raised shares of Sight Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Thursday, August 28th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.67.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.